Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Free Report) major shareholder Vivo Capital Viii, Llc sold 15,000 shares of the business’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $0.96, for a total value of $14,400.00. Following the completion of the transaction, the insider now owns 143,571 shares in the company, valued at approximately $137,828.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Vivo Capital Viii, Llc also recently made the following trade(s):
- On Monday, November 20th, Vivo Capital Viii, Llc sold 54,700 shares of Bolt Biotherapeutics stock. The shares were sold at an average price of $0.92, for a total value of $50,324.00.
Bolt Biotherapeutics Stock Down 3.2 %
BOLT opened at $0.91 on Tuesday. Bolt Biotherapeutics, Inc. has a twelve month low of $0.86 and a twelve month high of $2.03. The company has a debt-to-equity ratio of 0.14, a quick ratio of 7.42 and a current ratio of 6.69. The business has a 50 day moving average price of $1.01 and a 200 day moving average price of $1.28. The firm has a market cap of $34.73 million, a P/E ratio of -0.48 and a beta of 0.83.
Analyst Upgrades and Downgrades
Institutional Trading of Bolt Biotherapeutics
Institutional investors and hedge funds have recently modified their holdings of the company. Occudo Quantitative Strategies LP lifted its position in Bolt Biotherapeutics by 19.5% during the 2nd quarter. Occudo Quantitative Strategies LP now owns 30,816 shares of the company’s stock worth $63,000 after acquiring an additional 5,028 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Bolt Biotherapeutics by 13.0% in the first quarter. Bank of New York Mellon Corp now owns 91,293 shares of the company’s stock valued at $249,000 after purchasing an additional 10,475 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Bolt Biotherapeutics by 130.4% in the third quarter. Tower Research Capital LLC TRC now owns 18,537 shares of the company’s stock worth $28,000 after purchasing an additional 10,492 shares during the period. Geode Capital Management LLC lifted its position in shares of Bolt Biotherapeutics by 8.3% during the 4th quarter. Geode Capital Management LLC now owns 154,076 shares of the company’s stock worth $200,000 after purchasing an additional 11,853 shares during the last quarter. Finally, PDT Partners LLC bought a new stake in Bolt Biotherapeutics during the 1st quarter valued at approximately $33,000. 73.56% of the stock is currently owned by institutional investors and hedge funds.
Bolt Biotherapeutics Company Profile
Bolt Biotherapeutics, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.
- Five stocks we like better than Bolt Biotherapeutics
- How to Invest in Renewable Energy
- The most upgraded stocks in November have two things in common
- What Are Dividend Achievers? An Introduction
- Monday.com rocked earnings like it’s the weekend
- Overbought Stocks Explained: Should You Trade Them?
- Plan to own one retailer? Make it this one
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.